Herpes is one of the most common viral infections in the world, yet it remains widely misunderstood. Caused by the herpes ...
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...
Clinical Trials Arena on MSN
AiCuris reports positive Phase III pritelivir results for HSV patients
The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.
Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.
A recent international research project has used advanced microscopy techniques and computational modeling to discover why ...
People have shared their own warnings after a newborn baby was infected with a lethal virus just weeks into her life. Stacey ...
Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...
Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG ("Aicuris") today announced that the company will be presenting the results of pritelivir from their pivotal Phase 3 trial (PRIOH ...
News Medical on MSN
Study clarifies role of steroids in treating HSV encephalitis
A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation), caused by herpes simplex virus (HSV) does not ...
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results